BRAF and neoplasm: Recent studies demonstrated that response to BRAF+MEKi in patients with germline CDKN2A PVs was not inferior to data from clinical trials and real-world studies [52], while the response rate to immunotherapy was superior in CDKN2A PVs carriers, likely due to an increased tumor mutational load [53].